The amalgamation is expected to create a future-ready, diversified CDMO platform with a technology-led focus across three high-growth verticals-Antibody Drug Conjugates
The new combination therapy offers a dual mechanism of action for superior intraocular pressure control
The acquisition of MDxK further strengthens the Business Unit’s position in the molecular diagnostics market
Subcutaneous pembrolizumab administered every six weeks with a median injection time of two minutes, in combination with chemotherapy, shows consistent results across reported efficacy and safety endpoints compared to IV KEYTRUDA in combination with chemotherapy
Positions Curium as leading manufacturer of Lu-177 isotope
Lexicon Pharmaceuticals announces exclusive license agreement with Novo Nordisk for LX9851
Dupixent (dupilumab) approved as the first-ever biologic medicine in Japan for patients with Chronic Obstructive Pulmonary Disease (COPD)
Bio-Thera will maintain responsibility for development, manufacturing, and supply of BAT2206 and BAT2506
Collaboration combines data, identity capture and Web 3.0 crypto technologies to enhance product safety, traceability, and data integrity for AI systems
Dr. Benjamin Bechem, already leading WeylChem Organica and European custom manufacturing sales
Subscribe To Our Newsletter & Stay Updated
